Kimberly-Clark Announces Third Quarter 2024 Results and Reaffirms 2024 Profit Outlook
Delivers net sales of $5.0 billion on 1 percent organic sales growthResults and outlook reflect strong in-market execution, effective cost management and productivity
DALLAS, Oct. 22, 2024 /PRNewswire/ -- Kimberly-Clark Corporation (NYSE: KMB) today reported third quarter 2024 results driven by market-leading consumption growth from pioneering, innovative new products, and leveraging sustained productivity momentum.
"Our third quarter results reflect strong execution across the business as we transform our organization," said Kimberly-Clark Chairman and CEO, Mike Hsu. "I'm very proud of our teams' ability to deliver organic top-and-bottom-line growth, driven by market share gains and improved productivity, even against the backdrop of a dynamic consumer environment."
Hsu continued, "With our Powering Care strategy in full swing, we are accelerating our innovation pipeline and reducing costs to deliver higher-quality consumer solutions for every price point, and simplifying our operational structure so that we can be faster and more responsive in our markets. We are on track to deliver strong operating profit, margin, and EPS growth in 2024 while investing to maintain our business momentum into 2025."
Quarter Highlights
Net sales of $5.0 billion were down 4 percent, with organic sales growth of 1 percent versus the prior year.
Reported gross margin was 36.0 percent, adjusted gross margin was 36.7 percent, up 90 basis points versus the prior year, driven by strong gross productivity gains.
Diluted earnings per share were $2.69; adjusted earnings per share were $1.83, up 5 percent versus prior year including a $0.07 year-on-year headwind from currency translation.
Third Quarter 2024 Results
Third quarter sales of $5.0 billion were 4 percent lower than the prior-year period, including negative impacts of approximately 3 percent from foreign currency translation and approximately 1 percent from the divestiture of the K-C Professional Personal Protective Equipment (PPE) business completed in July 2024. Organic sales increased 1 percent, driven by a 1 percent increase in price while volume and mix were in line with a year ago. Price-led gains reflected necessary pricing actions to address higher local costs in hyperinflationary economies, mainly in Argentina. Volume and mix were positive in Developed Markets (representing Australia, South Korea and Western/Central Europe) offset by a decline in North America while volumes in Developing and Emerging (D&E) markets were in line with year ago.
In North America, organic sales decreased 1 percent versus the prior year, driven by a 3 percent decline in K-C Professional and 1 percent in Consumer Tissue while Personal Care was in line with year ago.
In D&E markets, organic sales rose 8 percent reflecting pricing gains primarily in hyperinflationary economies. Organic sales for Developed Markets were 2 percent lower, driven by lower pricing that primarily reflected comparisons with temporary, energy surcharge-related price increases in Western Europe in the prior-year period partially offset by low single digit volume led gains.
Third quarter operating profit was $1.2 billion, including $565 million of gains from the divestiture of the PPE business. Adjusted operating profit increased by 5 percent despite an unfavorable impact of 4 percentage points from currency translation that was primarily driven by hyperinflationary economies. Excluding currency impacts, growth in adjusted operating profit reflected gross productivity gains, relatively neutral pricing net of cost inflation, supply chain related investments, as well as planned increases in marketing, research and general expenses.
Net interest expense was $49 million versus $56 million in the prior-year.
The third quarter effective tax rate was 20.5 percent. On an adjusted basis, the effective rate in the third quarter was 22.7 percent compared to 22.5 percent in the prior year.
Net income of equity companies was $48 million compared to $50 million in the prior-year period.
Diluted EPS was $2.69 on a reported basis and included a positive $1.34 impact from the sale of the PPE business, a negative $0.31 impact from costs related to the company's Transformation Initiative and a negative $0.17 impact from impairment of intangible assets. On an adjusted basis, EPS increased 5 percent to $1.83, driven primarily by the 5 percent increase in adjusted operating profit.
Year-To-Date Results
For the first nine months of the year, sales of $15.1 billion decreased 2 percent including negative impacts of approximately 4 percent from foreign currency translation and approximately 1 percent from divestitures. Organic sales grew 4 percent, driven by an approximately 2 percent increase in price, primarily in hyperinflationary economies, 1 percent from favorable product mix and 1 percent increase in volume.
Year-to-date operating profit was $2.7 billion, including $565 million of gains from the divestiture of the PPE business, and $359 million of costs related to the company's transformation initiative.
Year-to-date adjusted operating profit was $2.6 billion versus $2.3 billion in the prior year. This was an increase of 12 percent versus prior year including an unfavorable impact of 8 percentage points from currency translation, primarily driven by hyperinflationary economies. Excluding currency impacts, the growth in adjusted operating profit was driven by a combination of organic growth and strong productivity savings that were partially offset by input cost inflation, primarily in D&E markets, supply chain related investments, impact of divestitures and planned increases in marketing, research and general expenses.
Through the first nine months of the year, diluted earnings per share were $6.21 in 2024 compared to $3.70 last year. Year-to-date adjusted earnings per share were $5.80 compared to $5.06 last year.
Business Segment Net Sales Results
Q3 change vs year ago (%)
Volume
Mix/Other
Net Price
Divestitures and Business Exits(a)
Currency Translation
Total(b)
Organic(c)
Personal Care
—
1
3
—
(6)
(2)
3
North America
—
1
(1)
—
—
(1)
—
D&E Markets
—
—
11
—
(15)
(4)
11
Developed Markets
—
1
(4)
—
(1)
(4)
(3)
Consumer Tissue
—
—
(1)
—
—
(2)
(1)
North America
(2)
—
1
—
—
(1)
(1)
D&E Markets
4
—
(4)
(1)
(1)
(3)
(1)
Developed Markets
3
—
(5)
—
(1)
(3)
(2)
K-C Professional
(1)
—
(1)
(7)
(2)
(10)
(1)
North America
(2)
—
(1)
(9)
—
(11)
(3)
D&E Markets
(6)
1
9
(4)
(9)
(9)
4
Developed Markets
7
—
(8)
(6)
(1)
(7)
(1)
Consolidated
—
—
1
(1)
(3)
(4)
1
YTD change vs year ago (%)
Volume
Mix/Other
Net Price
Divestitures and Business Exits(a)
Currency Translation
Total(b)
Organic(c)
Personal Care
1
1
5
—
(8)
(1)
7
North America
2
1
—
—
—
2
2
D&E Markets
2
1
14
—
(20)
(3)
17
Developed Markets
(1)
—
(2)
—
(2)
(5)
(3)
Consumer Tissue
—
—
(1)
(2)
—
(3)
(1)
North America
(1)
—
2
—
—
1
1
D&E Markets
(2)
—
(3)
(9)
(1)
(15)
(6)
Developed Markets
3
—
(5)
—
—
(2)
(2)
K-C Professional
(1)
1
—
(4)
(2)
(6)
—
North America
(3)
—
—
(3)
—
(5)
(3)
D&E Markets
—
1
11
(11)
(11)
(10)
13
Developed Markets
4
1
(7)
(2)
(1)
(5)
(2)
Consolidated
1
1
2
(1)
(4)
(2)
4
(a)
Impact of the sale of the Brazil tissue and K-C Professional business, sale of the PPE business and other exited businesses and markets in conjunction with the 2024 Transformation Initiative.
(b)
Total may not equal the sum of volume, mix/other, net price, divestitures and business exits and currency due to rounding and excludes intergeographic sales.
(c)
Combined impact of changes in volume, mix/other and net price excluding prior year's impact of divestitures and business exits.
Unaudited
Personal Care Segment
Personal Care sales of $2.6 billion decreased 2 percent in the quarter, while organic sales increased 3 percent from a combination of pricing actions in hyperinflationary economies as well as mix gains while volume was in line with year ago across all markets. Product innovation and solid commercial execution resulted in Baby and Child Care gaining global weighted market share on a year-to-date basis.
Third quarter operating profit of $482 million decreased 4 percent driven by a step up in advertising investment partially offset by optimization in overheads while gross profit was broadly in line with year ago.
Consumer Tissue Segment
Consumer Tissue sales of $1.5 billion decreased 2 percent, with a decline in organic sales of 1 percent. Organic decline was driven by retailer inventory reductions in North America as well as expected lower pricing in Western Europe due to lapping of temporary pricing related to energy surcharges in the prior year period.
Third quarter operating profit of $265 million decreased 1 percent, with gross productivity gains offset by higher manufacturing costs and increased advertising levels.
K-C Professional (KCP) Segment
KCP sales of $767 million decreased 10 percent due to divestitures and business exits as well as unfavorable currency impacts. Organic sales decreased 1 percent driven by 1 percent unfavorable price impact due to lapping of energy surcharges in Western Europe.
Third quarter operating profit of $161 million decreased 4 percent primarily impacted by the divestiture of the PPE business, underlying operating profit benefited from productivity gains partially offset by volume softness.
Cash Flow and Balance Sheet
Year-to-date cash provided by operations was $2.4 billion compared to $2.3 billion last year driven primarily by stronger operating results. Year-to-date capital spending was $512 million compared to $549 million last year. The company returned $2.0 billion to shareholders through dividends and repurchases of common stock. Total debt was $7.5 billion as of September 30, 2024, down from $8.0 billion as of December 31, 2023.
2024 Outlook
Based on its year-to-date results, the company has updated its 2024 outlook, with all factors compared to 2023, as follows:
Organic Net Sales are expected to grow between 3%-4% versus a mid-single digit rate previously, primarily reflecting discrete headwinds from changes in retail inventory levels. Reported Net Sales are still expected to be negatively impacted by 400 basis points of ...
